Category: PMCPA Case of the Week

Cases selected for the AskAnzal weekly PMCPA insight newsletter

8 Mar 2026

AUTH/3259/10/19: Complainant v Otsuka Europe β€” Jinarc (tolvaptan) risk minimisation materials (No breach)

Employee alleged Jinarc EU risk minimisation materials omitted pregnancy/dehydration info and that Otsuka lacked urgency on patient safety.…

8 Mar 2026

Alnylam: Agency LinkedIn post promoted Oxlumo to the public (breach of Clause 26.1; no breach of Clauses 2 and 9.1)

A subcontracted agency posted Oxlumo brand/indication details on LinkedIn. PMCPA ruled promotion of a POM to the public…

8 Mar 2026

Pfizer press release on COVID-19 vaccine efficacy ruled misleading for omitting absolute risk context (AUTH/3519/5/21)

PMCPA found Pfizer’s 2 Dec 2020 COVID-19 vaccine press release breached Clause 7.2 and 9.1 for presenting relative…

8 Mar 2026

AUTH/3634/4/22: Complainant v Daiichi Sankyo β€” Edoxaban (Lixiana) initiation leavepiece (no breach on narrow availability point)

Complaint said an edoxaban initiation leavepiece omitted hepatic considerations. Panel had concerns but ruled no breach because there…

8 Mar 2026

AUTH/3755/3/23: Health Professional v Novo Nordisk β€” funding alleged to induce prescribing (No breach)

Complaint alleged Novo Nordisk funded an obesity practitioner’s salary to induce prescribing and influenced local liraglutide criteria. Panel…

8 Mar 2026

AUTH/3870/1/24: Complainant v AstraZeneca β€” Allegations about clinical trial material (Out of scope)

PMCPA case AUTH/3870/1/24 against AstraZeneca concerned allegations about clinical trial material. The matter was found outwith the scope…

8 Mar 2026

Jazz Pharmaceuticals: Epidyolex HCP videos ruled misleading due to omitted hepatic contraindication and dose adjustment/discontinuation guidance (AUTH/3917/6/24)

Two Jazz-funded promotional/educational HCP videos for Epidyolex omitted key SPC liver contraindication and management guidance for concomitant valproate…

8 Mar 2026

AUTH/2153/8/08: Actonel leavepiece and use of draft NICE recommendations (Procter & Gamble)

A pharmacist challenged an Actonel leavepiece citing NICE July 2008. The Panel found the title and quotations misleading,…

8 Mar 2026

AstraZeneca: Crestor journal ad β€œFinding cholesterol targets harder to hit?” (AUTH/2186/11/08) – No breach

A pharmacist alleged a Crestor journal ad implied NICE cholesterol targets had been reduced and omitted first-line NICE…

8 Mar 2026

AUTH/2281/11/09: Anonymous Doctor v Lundbeck – conduct of representative (no breach)

A hospital doctor alleged a Lundbeck rep made a joint visit with a competitor rep and discussed rival…

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training